(redirected from Fazaclo)
Also found in: Dictionary, Thesaurus.
Related to Fazaclo: Clozaril


a sedative and antipsychotic agent of the dibenzodiazepine group; used in the treatment of schizophrenia.


Apo-Clozapine (CA) Clozaril, Denazapine (UK), Fazaclo ODT, Gen-Clozapine (CA) PMS-Clozapine (CA), Zaponex (UK)

Pharmacologic class: Dibenzodiazepine derivative

Therapeutic class: Antipsychotic agent

Pregnancy risk category B

FDA Box Warning

• Because of significant agranulocytosis risk, use only to treat severely ill patients with schizophrenia who don't respond to standard antipsychotic drugs, or to reduce risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who risk reexperiencing suicidal behavior. Obtain baseline white blood cell (WBC) and absolute neutrophil counts before therapy, regularly during therapy, and for at least 4 weeks afterward.

• Drug is associated with seizures; likelihood increases at higher doses. Use caution when giving to patients with history of seizures or other predisposing factors. Instruct patient not to engage in activities in which sudden loss of consciousness could cause serious risk to self or others.

• Drug may increase risk of fatal myocarditis, especially during first month of therapy. Discontinue promptly if myocarditis is suspected.

• Orthostatic hypotension with or without syncope may occur. Rarely, collapse is profound and accompanied by respiratory or cardiac arrest, or both. Orthostatic hypotension is more likely during initial titration when dosage is raised rapidly. In patients who've had even brief interval off drug (2 or more days since last dose), start with 12.5 mg once or twice daily.

• During initial therapy, collapse and respiratory and cardiac arrest may occur. Use caution when initiating therapy.

• Drug increased risk of death in elderly patients with dementia-related psychosis; most deaths have been cardiovascular or infectious. Drug isn't approved for dementia-related psychosis.


Unclear. Thought to interfere with dopamine binding in limbic system of CNS, with high affinity for dopamine4 receptors. May antagonize adrenergic, cholinergic, histaminergic, and serotonergic receptors.


Tablets: 25 mg, 50 mg, 100 mg, 200 mg

Tablets (orally disintegrating): 12.5 mg, 25 mg, 100 mg

Indications and dosages

Schizophrenia in patients unresponsive to other therapies

Adults: 12.5 mg P.O. daily or b.i.d.; increase daily in 25-to 50-mg increments, as tolerated, to target dosage of 300 to 450 mg/day by end of second week. Make subsequent dosage increases once or twice weekly in increments of 100 mg or less, to a maximum dosage of 900 mg/day P.O. in divided doses.

Dosage adjustment

• Renal impairment
• Elderly patients


• Hypersensitivity to drug
• Uncontrolled seizures
• Severe CNS depression or coma
• Paralytic ileus, myeloproliferative disorders, history of clozapine-induced agranulocytosis or severe granulocytopenia
• Concurrent use of drugs that cause agranulocytosis or bone marrow depression


Use cautiously in:
• hypersensitivity to phenothiazines
• cardiac, hepatic, or renal impairment; CNS tumors; diabetes mellitus; history of seizures; prostatic hypertrophy; intestinal obstruction; angle-closure glaucoma, patients with a history of long QT syndrome or prolonged QT interval or other conditions that may increase risk of prolonged QT interval or sudden death
• elderly patients
• pregnant or breastfeeding patients
• children.


Obtain WBC count before starting therapy. Don't give drug if WBC count is below 3,500/mm3.
• When discontinuing drug, taper dosage gradually over 1 to 2 weeks.
• Be aware that orally disintegrating tablets are meant to dissolve in mouth.

Adverse reactions

CNS: sedation, drowsiness, dizziness, vertigo, headache, tremor, insomnia, disturbed sleep, nightmares, agitation, lethargy, fatigue, weakness, confusion, anxiety, parkinsonism, slurred speech, depression, restlessness, extrapyramidal reactions, tardive dyskinesia, akathisia, syncope, neuroleptic malignant syndrome, autonomic disturbances, seizures

CV: hypotension, tachycardia, ECG changes, chest pain, QT-interval prolongation, myocarditis

EENT: blurred vision, dry eyes, nasal congestion, sinusitis

GI: nausea, vomiting, constipation, dyspepsia, salivation, dry mouth, anorexia

GU: urinary retention, urinary incontinence, urinary frequency and urgency, inhibited ejaculation

Musculoskeletal: muscle spasms, rigidity, back and muscle pain

Hematologic: agranulocytosis, leukopenia, hemolytic anemia, aplastic anemia, thrombocytopenia, neutropenia, eosinophilia

Respiratory: dyspnea, respiratory arrest

Skin: rash, sweating, Stevens-Johnson syndrome

Other: weight gain, fever


Drug-drug.Anticholinergics, antihypertensives, digoxin, warfarin: increased effects of these drugs

Cimetidine, erythromycin: increased therapeutic and toxic effects of clozapine

Epinephrine: increased hypotension

Fluoxetine, fluvoxamine, paroxetine, sertraline: increased clozapine blood level

Phenytoin, rifampin: decreased clozapine blood level

Psychoactive drugs: additive psychoactive effect

Drug-diagnostic tests.Granulocytes, hematocrit, hemoglobin, platelets, white blood cells: decreased values

Liver function tests: abnormal values

Pregnancy test: false-positive result

Drug-food.Caffeine: increased clozapine blood level

Drug-herbs.Angel's trumpet, Jimsonweed, scopolia: increased anticholinergic effects

Nutmeg: decreased clozapine efficacy St. John's wort: decreased clozapine blood level

Drug-behaviors.Alcohol use: increased CNS depression

Smoking: decreased clozapine blood level

Patient monitoring

Monitor WBC count weekly for first 6 months of therapy; if it's normal, WBC testing can be reduced to every other week. Notify prescriber immediately if WBC count decreases or agranulocytosis occurs.
• Monitor ECG and liver function test results.
• If drug must be withdrawn abruptly, monitor patient for psychosis and cholinergic rebound (headache, nausea, vomiting, diarrhea).
• Continue to monitor WBC count weekly for 4 weeks after therapy ends.

Patient teaching

• Tell patient to allow orally disintegrating tablet to dissolve in mouth.
• Teach patient about significant risk of agranulocytosis; tell him he'll need to undergo weekly blood testing to check for this blood disorder. Mention that clozapine tablets are available only through a special program that ensures required blood monitoring.

Advise patient to immediately report new onset of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulcers, flulike symptoms, or other signs and symptoms of infection.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.


/clo·za·pine/ (klo´zah-pēn) a sedative and antipsychotic agent; used in the treatment of schizophrenia.


(klō′zə-pēn′, -pĭn)
An antipsychotic drug used as a sedative and in the treatment of schizophrenia.


Clozaril® Psychiatry A dibenzodiazepine antipsychotic and sedative, and effective neuroleptic for acutely psychotic and treatment-resistant schizophrenics, without extrapyramidal effects–dystonia, parkinsonism, tardive dyskinesia or ↑ prolactin levels Adverse effects Hypotension, hypersalivation, sedation, agranulocytosis–1% of Pts, tachycardia, weight gain. See Bundling, Positive and Negative Symptom Scale, Schizophrenia. Cf Haloperidol.


An antipsychotic drug notable for its absence of side effects such as tremors and repetitive movements (dyskinesias). It does, however, tend to affect white blood cell production and regular blood checks are necessary. Between 1 and 2 per cent of those taking the drug suffer a drop in white cell count. This returns to normal within a month of stopping the drug. Clozapine can restore people to an almost normal life after years of intractable SCHIZOPHRENIA. A brand name is Clozaril.

clozapine (klō´zəpēn´),

n brand name: Clozaril;
drug class: antipsychotic, atypical;
action: interferes with binding of dopamine at D1 and D2 receptors; acts as adrenergic, cholinergic, histaminergic, and serotonergic antagonist;
uses: management of psychotic symptoms in schizophrenic patients for whom other antipsychotics have failed.
References in periodicals archive ?
There can be no assurance that the proceeds received by the Company from the recent sale of the Company's FazaClo operations, together with the Company's other available funds, will be sufficient to fund the Company's operations as currently anticipated, or that the Company will be able to complete planned clinical trials within the projected time periods.
After the end of the quarter, the Company raised additional proceeds of approximately $31 million from the sale of FazaClo, net of $11 million in debt pay-down related to the 2006 Alamo acquisition.
There can be no assurance that the proceeds received by the Company from the sale of the Company's FazaClo operations, together with the Company's other available funds, will be sufficient to fund the Company's operations as currently anticipated, or that the Company will be able to commence and complete planned clinical trials within the projected time periods.
There can be no absolute assurance that the proceeds received by the Company from the sale of the Company's FazaClo operations, together with the Company's other available funds, will be sufficient to fund the Company's operations as currently anticipated, or that the Company will be able to commence and complete planned clinical trials within the projected time periods.
The divestiture of FazaClo marks an important step forward in our corporate strategy to direct our resources toward the Zenvia[TM] development programs," said Keith Katkin, AVANIR's President and CEO.
We have accomplished a great deal since acquiring FazaClo just over a year ago for $29 million plus $4 million in contingent run rate notes.
In light of the reduced operating infrastructure anticipated following the sale of FazaClo, the Company announced that Mike Puntoriero, Senior Vice President and Chief Financial Officer, will be resigning his position with AVANIR effective July 11, 2007.
The new formulation and packaging should improve the utility of FazaClo and make it easier to offer to patients within my practice," said Michael J.
AVANIR received an approvable letter in January 2007 for this new formulation of FazaClo.
FazaClo total prescription volume increased 52% over the same quarter last year and 15% over the previous fiscal quarter.
Announced that the Company is in discussions with several parties that have expressed interest in potentially acquiring certain Company assets, including FazaClo and several investigational compounds.